Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change.
We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views.
We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.
We don't currently have any active consultations, but check back here regularly for updates.
|
Title: All Wales Medicine Management Guidelines for Integrated Community Based Services Status: Consultation completed Remit: This guideline is focused on community care and designed to address the unique needs and challenges faced by registered service providers ensuring consistent medicine advice in diverse care settings. Specifically designed to guide local policy development, this guideline aims to establish a unified and integrated policy across health and social care, providing comprehensive guidance for medicine optimisation. Estimated publication date: June 2025-August 2025 |
|
Title: Managing medicines shortages in Wales Status: Consultation completed Remit: This project aims to develop a patient information leaflet to inform people in Wales about what happens if there is a shortage of a medicine in Wales, and the processes involved. The leaflet is intended for all patients, and their families and carers, in Wales. And also for healthcare professionals in Wales who are involved in prescribing and dispensing medicines for which there is a medicine shortage. Estimated publication date: February -March 2025 |
|
Title: Urgent Requests for Repeat Medication – Guidance for community pharmacy, NHS 111 and out-of-hours primary care services Status: Consultation completed Remit: Urgent requests for repeat medication are a major burden to NHS 111 and out-of-hours (OOH) primary care services. This document outlines factors to be considered by healthcare professionals when deciding whether to prescribe urgent repeat medication at the request of a patient. Estimated publication date: March 2025–May 2025 |
|
Title: All Wales Shared Care Framework Status: Consultation anticipated March 2025–May 2025 Remit: To review and refine the current principles for the use of shared care within NHS Wales and to develop an All Wales framework that sets out the principles of shared care and supports health boards and prescribers in the appropriate use of shared care. Estimated publication date: June 2025-August 2025 |
|
Title: All Wales Common Ailments Service Formulary - Monograph for allergic rhinitis (consultation) Status: Consultation completed Remit: The Common Ailments Service aims to improve patient access to consistent, evidence-based advice for the management of common ailments. The Welsh Medicines Advice Service (WMAS), in collaboration with the Community Pharmacy Clinical Advisory Group, have updated the allergic rhinitis monograph to include fexofenadine as a treatment option. The referral, treatment and formulary information have been re-designed based on user feedback. Estimated publication date: April-May 2025 |
|
Title: Policy for the sustainable procurement, management, administration and disposal of medical gases within the hospital setting to achieve decarbonisation Status: Consultation completed Remit: This document targets the procurement and management of medical gases. While the principles and recommendations could be applied to many medical gases, this policy focuses on nitrous oxide and Entonox®, as these gases have the highest impact due to high global warming potential and high-volume usage. Estimated publication date: April-May 2025 |
|
Medicine name: teriparatide Reference number: 306 Indication: Treatment of osteoporosis in men at increased risk of fracture. Licence status: Licensed for the indication under consideration AWMSG Scrutiny Panel meeting date: 06/02/2025 |
|
Medicine name: trametinib (Mekinist®) Reference number: 6321 Indication: For the off-label treatment of recurrent low grade serous ovarian carcinoma (LGSOC) which has progressed following at least 1 previous platinum-based regimen. Licence status: Off-label for the indication under consideration AWMSG Scrutiny Panel meeting date: 06/02/2025 |
Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.
Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.
We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.
|
Medicine name: ziconotide (Prialt®) Reference number: 5385 (reassessment of 335) Indication: Treatment of severe, chronic pain in adults who require intrathecal (IT) analgesia Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form NMG meeting date: 20/03/2025 AWMSG meeting date: 20/05/2025 |
|
Medicine name: guanfacine (Intuniv®) Reference number: 6440 (reassessment of 2361) Indication: Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Intuniv® must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures. Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form LOWMAG meeting date: TBC AWMSG meeting date: TBC |
|
Medicine name: abiraterone (generic) Reference number: 6441 Indication: With prednisolone for the treatment of newly-diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form LOWMAG meeting date: TBC AWMSG meeting date: TBC |
|
Medicine name: panitumumab (Vectibix®) Reference number: OW29 Indication: For the off-label third line or later treatment of metastatic colorectal cancer (mCRC) as a re-challenge after previous successful first-line use of an epidermal growth factor receptor inhibitor (EGFRi). Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: TBC OWMAG date: TBC AWMSG date: TBC |
|
Title: AWMSG annual report 2024-2025 Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2023 and March 2024. Estimated publication date: September 2025 |
|
Title: IPFR annual report 2024-2025 Summary: Review of Individual Patient Funding Request activity in Wales between April 2023 and March 2024. Estimated publication date: September 2025 |